These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 5938056)

  • 41. A short trial assessment of uricosuric therapy in gout.
    Palmer DG; Highton TC
    Australas Ann Med; 1968 Aug; 17(3):242-7. PubMed ID: 5684610
    [No Abstract]   [Full Text] [Related]  

  • 42. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of long-term base therapy on the clinical picture of gout].
    Baiatova KV
    Ter Arkh; 1981; 53(2):87-91. PubMed ID: 7221944
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
    Hilmi BA; Asmahan MI; Rosman A
    Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allopurinol in the treatment of gout.
    Woodbury JF; Mehta DM; Morse WI
    N S Med Bull; 1969 Aug; 48(4):103-7. PubMed ID: 5258764
    [No Abstract]   [Full Text] [Related]  

  • 46. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Carroll MB; Smith DM; Shaak TL
    Rheumatol Int; 2017 Mar; 37(3):445-453. PubMed ID: 27798726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Allopurinol].
    Scott JT
    Schweiz Med Wochenschr; 1967 Dec; 97(49):1659-62. PubMed ID: 5596893
    [No Abstract]   [Full Text] [Related]  

  • 48. The treatment of gout.
    Wallace SL
    Arthritis Rheum; 1972; 15(3):317-23. PubMed ID: 5031616
    [No Abstract]   [Full Text] [Related]  

  • 49. Milestones in the treatment of gout.
    Yü T; Yu TF
    Am J Med; 1974 May; 56(5):676-85. PubMed ID: 4604776
    [No Abstract]   [Full Text] [Related]  

  • 50. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
    Kydd AS; Seth R; Buchbinder R; Falzon L; Edwards CJ; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():33-41. PubMed ID: 25180126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. THE RENAL EXCRETION OF OXYPURINES.
    GOLDFINGER S; KLINENBERG JR; SEEGMILLER JE
    J Clin Invest; 1965 Apr; 44(4):623-8. PubMed ID: 14278178
    [No Abstract]   [Full Text] [Related]  

  • 55. [Our experience in the treatment of hyperuricemia with a xanthine oxidase inhibitor (HPP), Allopurinol].
    Rapado Errazti A
    Rev Esp Reum Enferm Osteoartic; 1966 Oct; 11(8):304-6. PubMed ID: 5997999
    [No Abstract]   [Full Text] [Related]  

  • 56. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase].
    Royer R; Vindel J; Lamarche M; Kissel P
    Presse Med (1893); 1968 Dec; 76(49):2325-7. PubMed ID: 5737250
    [No Abstract]   [Full Text] [Related]  

  • 58. Zyloprim and other drugs in the management of gout.
    Med Lett Drugs Ther; 1966 Dec; 8(24):98-9. PubMed ID: 4292660
    [No Abstract]   [Full Text] [Related]  

  • 59. Allopurinal and acute uric acid nephropathy.
    Watts RW; Watkins PJ; Matthias JQ; Gibbs DA
    Br Med J; 1966 Jan; 1(5481):205-8. PubMed ID: 5901729
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of gout.
    Simkin PA
    Ann Intern Med; 1979 May; 90(5):812-6. PubMed ID: 434690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.